ACEA Therapeutics, located in San Diego, California, is a subsidiary of Sorrento and is dedicated to developing innovative treatments for patients with life-threatening diseases. Their lead compound, Abivertinib, is currently being reviewed by the China Food and Drug Administration for the treatment of non-small cell lung cancer with the EGFR T790M mutation, and is also undergoing clinical trials for Covid-19 treatment. ACEA Therapeutics also has a second compound, AC0058, in Phase 1B development for the treatment of systemic lupus erythematosus.
With a strong focus on research and development, ACEA Therapeutics has established manufacturing and commercial capabilities in China to ensure efficient supply chain management and timely delivery of their products to patients.
Generated from the website